X0508 4 2023-08-01 false 0001771917 Karuna Therapeutics, Inc. KRTX 0001042021 JONAS JEFFREY M C/O KARUNA THERAPEUTICS, INC. 99 HIGH STREET, 26TH FLOOR BOSTON MA 02110 true true Common Stock 2023-08-01 4 M false 13810 7.27 A 14800 D Common Stock 2023-08-01 4 S false 3399 194.78 D 11401 D Common Stock 2023-08-01 4 S false 6301 195.61 D 5100 D Common Stock 2023-08-01 4 S false 3110 196.59 D 1990 D Common Stock 2023-08-01 4 S false 400 197.66 D 1590 D Common Stock 2023-08-01 4 S false 600 198.41 D 990 D Option (right to buy) 7.27 2023-08-01 4 M false 13810 0 D 2028-09-30 Common Stock 13810 33702 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.11 to $195.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (6) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $195.11 to $196.08, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.11 to $197.07, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.12 to $198.08, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.18 to $198.58, inclusive. This option vested and became exercisable in eight equal installments on each six month anniversary of the vesting commencement date of September 20, 2018. /s/ Troy Ignelzi, Attorney-in-Fact 2023-08-02